Erratum: A novel aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373);A novel Aminotetralin-Type Serotonin (5-HT)2C receptor-specific Agonist and 5-HT2A competitive Antagonist/5-HT2B inverse agonist with preclinical efficacy for Psychoses

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 2, 2014, Pages 310-318

  Canal, Clinton E ^a   Morgan, Drake ^b   Felsing, Daniel ^c   Kondabolu, Krishnakanth ^c   Rowland, Neil E ^d   Robertson, Kimberly L ^d   Sakhuja, Rajeev ^c,e   Booth, Raymond G ^a,f  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Department of Psychiatry ^*  (United States)

^c Medicinal Chemistry   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e Boston University   (United States)

^f BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3' 4 BROMOPHENYL) N,N DIMETHYL 1,2,3,4 TETRAHYDRONAPHTHALEN 2 AMINE; CLOZAPINE; NEUROLEPTIC AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2B INVERSE AGONIST; SEROTONIN 2C AGONIST; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXPERIMENTAL HYPERACTIVITY; FOOD INTAKE; HEAD TWITCH; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PALATABILITY; PRIORITY JOURNAL; PSYCHOSIS;

2-NAPHTHYLAMINE; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; FEEDING BEHAVIOR; HEK293 CELLS; HUMANS; HYPERKINESIS; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; PSYCHOTIC DISORDERS; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; STEREOISOMERISM; TIME FACTORS;

EID: 84898813207     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.06er14     Document Type: Erratum

References (60)

1. Abdallah L, Bonasera SJ, Hopf FW, O'Dell L, Giorgetti M, Jongsma M, Carra S, Pierucci M, Di Giovanni G, and Esposito E, et al. (2009) Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. J Neurosci 29:8156-8165
2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, and Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
3. Aghajanian GK and Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312
4. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, and Pehek EA (2005) Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55:242-251
5. Arena Pharmaceuticals (2012) Arena Pharmaceuticals and Eisai announce FDA approval of BELVIQ® (lorcaserin HCl) for chronic weight management in adults who are overweight with a comorbidity or obese. http://invest.arenapharm. com/releasedetail.cfm?ReleaseID5687182 ed
6. Bellack AS (2006) Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull 32:432-442
7. Booth RG, Fang L, Huang Y, Wilczynski A, and Sivendran S (2009) (1R, 3S)-(2)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. Eur J Pharmacol 615: 1-9
8. Brown JW, Rueter LE, and Zhang M (2013) Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog Neuropsychopharmacol Biol Psychiatry 49:53-62
9. Canal CE, Booth RG, and Morgan D (2013) Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology 70:112-121
10. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
11. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, and Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-Aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120:67-74
12. Coyle JT, Basu A, Benneyworth M, Balu D, and Konopaske G (2012) Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol 213. 267-295 DOI: 10.1007/978-3-642-25758-2-10
13. CunninghamKA, AnastasioNC, FoxRG, Stutz SJ, Bubar MJ, Swinford SE,WatsonCS, Gilbertson SR, Rice KC, and Rosenzweig-Lipson S, et al. (2013) Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem Neurosci 4:110-121
14. Curran C, Byrappa N, and McBride A (2004) Stimulant psychosis: systematic review. Br J Psychiatry 185:196-204
15. De Deurwaerdére P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241
16. Di Giovanni G, Di Matteo V, Di Mascio M, and Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61
17. Di Giovanni G, Esposito E, and Di Matteo V (2011) The 5-HT2C receptor subtype controls central dopaminergic systems: evidence from electrophysiological and neurochemical studies in 5-HT2C Receptors in the Pathophysiology of CNS Disease (Di Giovanni G, Esposito E, and Di Matteo V, eds) pp 215-247, Humana Press, NewYork
18. Di Matteo V, Pierucci M, and Esposito E (2004) Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 89:418-429
19. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, and Schechter L, et al. (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi] indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862-869
20. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, and Higgins GA (2009) Characterizing the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice. Neuropharmacology 57:259-267
21. Gleason SD and Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84
22. Glennon RA, Titeler M, and McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505-2511
23. Gonzalez-Maeso J and Sealfon SC (2009) Psychedelics and schizophrenia. Trends Neurosci 32:225-232
24. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, and Powell SB (2009) 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 34:1958-1967
25. Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, and Fletcher PJ (2012) The 5-HT2C receptor agonist lorcaserin reduces nicotine self-Administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology 37:1177-1191
26. Kimura A, Stevenson PL, Carter RN, Maccoll G, French KL, Simons JP, Al-Shawi R, Kelly V, Chapman KE, and Holmes MC (2009) Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. Eur J Neurosci 30:299-306
27. Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O'Rahilly S, and Heisler LK (2007) Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149:1323-1328
28. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, and Geddes JR, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-Analysis. Lancet 382:951-962
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, and Lebowitz BD, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
30. Lindenmayer J-P (2000) Treatment refractory schizophrenia. Psychiatr Q 71: 373-384
31. López-Giménez JF, Mengod G, Palacios JM, and Vilaró MT (2001) Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 42:12-26
32. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Jr., Nguyen HQ, and Dawson LA, et al. (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7, 1hi] indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486-496
33. Masana M, Santana N, Artigas F, and Bortolozzi A (2012) Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review. Curr Top Med Chem 12:2357-2374
34. Molineaux SM, Jessell TM, Axel R, and Julius D (1989) 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 86:6793-6797
35. Morgan D, Kondabolu K, Kuipers A, Sakhuja R, Robertson KL, Rowland NE, and Booth RG (2013) Molecular and behavioral pharmacology of two novel orallyactive 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology 72:274-281
36. Moritz S, Andreou C, Klingberg S, Thoering T, and Peters MJ (2013) Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect? Neuropharmacology 72:179-186
37. Motulsky HJ and Christopoulos A (2003) Fitting Models to Biological Data Using Linear and Non-linear Regression: A Practical Guide to Curve-Fitting, GraphPad Software, San Diego, CA
38. Nichols CD (2009) Serotonin 5-HT2A receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases. Cardiovasc Psychiatry Neurol 2009: 475108
39. National Institute of Mental Health (NIMH) 2010) Mental Health Medications, U.S. Department of Health and Human Services, Bethesda,MD. http://www.nimh.nih.gov/health/publications/mental-health-medications/ nimh-mental-health-medications.pdf
40. Olaghere da Silva UB, Morabito MV, Canal CE, Airey DC, Emeson RB, and Sanders-Bush E 2010) Impact of RNA editing on functions of the serotonin 2C receptor in vivo. Front Neurosci 4 1-10
41. Olijslagers JE, Werkman TR, McCreary AC, Siarey R, Kruse CG, and Wadman WJ (2004) 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat. Neuropharmacology 46:504-510
42. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Faludi G, Sarosi A, and Palkovits M (2006) Regional distribution and relative abundance of serotonin(2c) receptors in human brain: effect of suicide. Neurochem Res 31:167-176
43. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, and Kieseppä T, et al. (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19-28
44. Pramyothin P and Khaodhiar L (2010) Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 17:460-466
45. Rojas-Corrales MO, Gibert-Rahola J, and Mico JA (2007) Role of atypical opiates in OCD. Experimental approach through the study of 5-HT2A/C receptor-mediated behavior. Psychopharmacology (Berl) 190:221-231
46. Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, and Dunlop J (2012) 5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia, in Novel Antischizophrenia Treatments (Geyer MA and Gross G, eds) pp 147-165, Springer, New York
47. Rothman RB and Baumann MH (2009) Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 8:317-329
48. Seeman MV and Seeman P (2014) Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry
49. Shen J, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams J, Giller E, Detke M, and Kane J (2010) A 6-Week Randomized, Double-Blind, Placebo-controlled, Comparator Referenced, Multicenter Trial of Vabicaserin in Subjects with Acute Exacerbation of Schizophrenia, ACNP, Waikoloa Beach, HI
50. Simpson EH, Kellendonk C, Ward RD, Richards V, Lipatova O, Fairhurst S, Kandel ER, and Balsam PD (2011) Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol Psychiatry 69: 928-935
51. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, and Swick A, et al. (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279-290
52. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, and Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med 363:245-256
53. Stip E, Lungu OV, Anselmo K, Letourneau G, Mendrek A, Stip B, Lipp O, Lalonde P, and Bentaleb LA (2012) Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2:e128
54. Strange PG (2008) Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci 29:314-321
55. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, and Chen W, et al. (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577-587
56. Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, and Andersson CM, et al. (2004) Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1- methyl-piperidin-4-yl)-Acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. J Pharmacol Exp Ther 310:943-951
57. Vincek AS and Booth RG (2009) New approach to 4-phenyl-b-Aminotetralin from 4-(3-halophenyl)tetralen-2-ol phenylacetate. Tetrahedron Lett 50:5107-5109
58. Williams AA, Ingram WM, Levine S, Resnik J, Kamel CM, Lish JR, Elizalde DI, Janowski SA, Shoker J, and Kozlenkov A, et al. (2012) Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine. Neuropsychopharmacology 37:2285-2298
59. Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ, Anderson JG, Heisler LK, Zigman JM, and Lowell BB, et al. (2008) 5-HT2CRs expressed by proopiomelanocortin neurons regulate energy homeostasis. Neuron 60:582-589
60. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, and Dunlop J (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71:521-529.